{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:47:52Z","timestamp":1788911272664,"version":"build-2803163510"},"reference-count":77,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2021.12925","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T20:43:56Z","timestamp":1626295436000},"source":"Crossref","is-referenced-by-count":14,"title":["Inhibition of photodynamic therapy induced\u2011immunosuppression with aminolevulinic acid leads to enhanced outcomes of tumors and pre\u2011cancerous lesions (Review)"],"prefix":"10.3892","volume":"22","author":[{"given":"Sharlo","family":"Bayless","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Travers","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Sahu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Rohan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"key20210811132356_b1-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/0959-8049(92)90080-L","article-title":"Photodynamic therapy","volume":"28","author":"Dougherty","year":"1992","journal-title":"Eur Cancer"},{"key":"key20210811132356_b2-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S1359-6446(99)01412-9","article-title":"Photodynamic therapeutics: Basic principles and clinical applications","volume":"4","author":"Sharman","year":"1999","journal-title":"Drug Disc Today"},{"key":"key20210811132356_b3-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1011-1344(96)07428-3","article-title":"Photophysical and photobiological processes in the photodynamic therapy of tumours","volume":"39","author":"Ochsner","year":"1997","journal-title":"J Photochem Photobiol B"},{"key":"key20210811132356_b4-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/j.1751-1097.1986.tb05647.x","article-title":"Porphyrin photosensitization and phototherapy","volume":"43","author":"Moan","year":"1986","journal-title":"Photochem Photobiol"},{"key":"key20210811132356_b5-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1572-1000(04)00007-9","article-title":"Photosensitizers in clinical PDT","volume":"1","author":"Allison","year":"2004","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"key20210811132356_b6-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.biopha.2018.07.049","article-title":"Photodynamic therapy-mechanisms, photosensitizers and combinations","volume":"106","author":"Kwiatkowski","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"key20210811132356_b7-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1042\/BJ20150942","article-title":"New photosensitizers for photodynamic therapy","volume":"473","author":"Abrahamse","year":"2016","journal-title":"Biochem J"},{"key":"key20210811132356_b8-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.apsb.2017.09.003","article-title":"An updated overview on the development of new photosensitizers for anticancer photodynamic therapy","volume":"8","author":"Zhang","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"key20210811132356_b9-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.addr.2008.08.003","article-title":"Nanoparticles in photodynamic therapy: An emerging paradigm","volume":"60","author":"Chatterjee","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"key20210811132356_b10-ol-0-0-12925","first-page":"44","article-title":"ALA-PDT and MAL-PDT: What makes them different","volume":"2","author":"Gold","year":"2009","journal-title":"J Clin Aesthet Dermatol"},{"key":"key20210811132356_b11-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"304862","DOI":"10.1155\/2014\/304862","article-title":"Overview on topical 5-ALA photodynamic therapy use for non melanoma skin cancers","volume":"2014","author":"Cantisani","year":"2014","journal-title":"Int J Photoen"},{"key":"key20210811132356_b12-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s40257-018-0360-y","article-title":"Daylight photodynamic therapy for actinic keratoses","volume":"19","author":"Morton","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"key20210811132356_b13-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/bjd.18537","article-title":"Comparing the efficacy of field treatments for actinic keratosis: A critical appraisal of a randomized trial in the New England Journal of Medicine","volume":"182","author":"Wehner","year":"2020","journal-title":"Br J Dermatol"},{"key":"key20210811132356_b14-ol-0-0-12925","first-page":"S8","article-title":"Photodynamic therapy in dermatology: History and horizons","volume":"3","author":"Taub","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"key20210811132356_b15-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1136\/bjo.2003.038604","article-title":"A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration","volume":"88","author":"Armbrecht","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"key20210811132356_b16-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1093\/jnci\/94.23.1740","article-title":"Studies expand potential uses of photodynamic therapy","volume":"94","author":"McBride","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"key20210811132356_b17-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"27005","DOI":"10.3390\/ijms161126008","article-title":"Immunoregulatory cell depletion improves the efficacy of photodynamic therapy-generated cancer vaccines","volume":"16","author":"Korbelik","year":"2015","journal-title":"Int J Mol Sci"},{"key":"key20210811132356_b18-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00262-020-02528-5","article-title":"Inhibition of IDO leads to IL-6-dependent systemic inflammation in mice when combined with photodynamic therapy","volume":"69","author":"Wachowska","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"key20210811132356_b19-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1751-1097.1999.tb01951.x","article-title":"Immunosuppressive effects of silicon phthalocyanine photodynamic therapy","volume":"70","author":"Reddan","year":"1999","journal-title":"Photochem Photobiol"},{"key":"key20210811132356_b20-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1751-1097.1989.tb09194.x","article-title":"Systemic immunosuppression induced by photodynamic therapy (PDT) is adoptively transferred by macrophages","volume":"49","author":"Lynch","year":"1989","journal-title":"Photochem Photobiol"},{"key":"key20210811132356_b21-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1038\/bjc.2013.580","article-title":"Photodynamic therapy plus regulatory T-cell depletion produces immunity against a mouse tumour that expresses a self-antigen","volume":"109","author":"Reginato","year":"2013","journal-title":"Br J Cancer"},{"key":"key20210811132356_b22-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1039\/c0pp00345j","article-title":"The immunosuppressive side of PDT","volume":"10","author":"Mroz","year":"2011","journal-title":"Photochem Photobiol Sci"},{"key":"key20210811132356_b23-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/php.13253","article-title":"Photodynamic therapy and immunity: An update","volume":"96","author":"Falk-Mahapatra","year":"2020","journal-title":"Photochem Photobiol"},{"key":"key20210811132356_b24-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1600-0781.2010.00552.x","article-title":"Herpes simplex virus reactivation as a complication of photodynamic therapy","volume":"27","author":"Nobbe","year":"2011","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"key20210811132356_b25-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000246057","article-title":"Development of malignant melanoma after repeated topical photodynamic therapy with 5-Aminolevulinic acid at the exposed site","volume":"194","author":"Wolf","year":"1997","journal-title":"Dermatology"},{"key":"key20210811132356_b26-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000339335","article-title":"Facial basal cell carcinomas recurring after photodynamic therapy: A retrospective analysis of histological subtypes","volume":"224","author":"Fiechter","year":"2012","journal-title":"Dermatology"},{"key":"key20210811132356_b27-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"5495","DOI":"10.1073\/pnas.0709256105","article-title":"Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model","volume":"105","author":"Castano","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20210811132356_b28-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"119845","DOI":"10.1016\/j.biomaterials.2020.119845","article-title":"Photodynamic therapy produces enhanced efficacy of antitumor immunotherapy by simultaneously inducing intratumoral release of sorafenib","volume":"240","author":"Sun","year":"2020","journal-title":"Biomaterials"},{"key":"key20210811132356_b29-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/imm.12036","article-title":"The immunosuppressive tumour network: Myeloid-derived suppressor cells, regulatory T cells and natural killer T cells","volume":"138","author":"Lindau","year":"2013","journal-title":"Immunology"},{"key":"key20210811132356_b30-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/j.1582-4934.2011.01437.x","article-title":"Regulatory T cell: A protection for tumour cells","volume":"16","author":"Wang","year":"2012","journal-title":"J Cell Mol Med"},{"key":"key20210811132356_b31-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1016\/j.celrep.2016.11.062","article-title":"Myeloid-derived suppressor cells are controlled by regulatory T cells via TGF-\u03b2 during murine colitis","volume":"17","author":"Lee","year":"2016","journal-title":"Cell Rep"},{"key":"key20210811132356_b32-ol-0-0-12925","first-page":"1433","article-title":"Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth","volume":"1","author":"Fujimura","year":"2012","journal-title":"Onco Immunol"},{"key":"key20210811132356_b33-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/jid.2014.313","article-title":"Topical photodynamic therapy induces systemic immunosuppression via generation of platelet-activating factor receptor ligands","volume":"135","author":"Ferracini","year":"2015","journal-title":"J Invest Dermatol"},{"key":"key20210811132356_b34-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.4049\/jimmunol.1202699","article-title":"Cigarette smoke exposure inhibits contact hypersensitivity via the generation of platelet-activating factor agonists","volume":"190","author":"Sahu","year":"2013","journal-title":"J Immunol"},{"key":"key20210811132356_b35-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1038\/sj.jid.5701251","article-title":"UVB radiation-mediated inhibition of contact hypersensitivity reactions is dependent on the platelet-activating factor system","volume":"128","author":"Zhang","year":"2008","journal-title":"J Invest Dermatol"},{"key":"key20210811132356_b36-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-dependent tumor growth through evasion of immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"key":"key20210811132356_b37-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"12203","DOI":"10.1007\/s13277-016-5087-x","article-title":"Prostaglandin E2 (PGE2) promotes proliferation and invasion by enhancing SUMO-1 activity via EP4 receptor in endometrial cancer","volume":"37","author":"Ke","year":"2016","journal-title":"Tumor Biol"},{"key":"key20210811132356_b38-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1158\/0008-5472.CAN-10-3055","article-title":"COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells","volume":"71","author":"Fujita","year":"2011","journal-title":"Cancer Res"},{"key":"key20210811132356_b39-ol-0-0-12925","first-page":"5417","article-title":"Inhibition of cyclooxygenase-2 indirectly potentiates antitumor effects of photodynamic therapy in mice","volume":"9","author":"Makowski","year":"2003","journal-title":"Clin Cancer Res"},{"key":"key20210811132356_b40-ol-0-0-12925","first-page":"3","article-title":"Regulatory T cells: Molecular and cellular basis for immunoregulation","volume":"410","author":"Togashi","year":"2017","journal-title":"Curr Top Microbiol Immunol"},{"key":"key20210811132356_b41-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"7983","DOI":"10.1002\/jcp.27553","article-title":"Contribution of regulatory T cells to cancer: A review","volume":"234","author":"Najafi","year":"2019","journal-title":"J Cell Physiol"},{"key":"key20210811132356_b42-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/imm.13058","article-title":"Treg programming and therapeutic reprogramming in cancer","volume":"157","author":"Moreno Ayala","year":"2019","journal-title":"Immunology"},{"key":"key20210811132356_b43-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s11427-018-9428-9","article-title":"The function and potential drug targets of tumour-associated Tregs for cancer immunotherapy","volume":"62","author":"Yan","year":"2019","journal-title":"Sci China Life Sci"},{"key":"key20210811132356_b44-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"47440","DOI":"10.18632\/oncotarget.17663","article-title":"Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responses","volume":"8","author":"Oh","year":"2017","journal-title":"Oncotarget"},{"key":"key20210811132356_b45-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3389\/fimmu.2017.01360","article-title":"Indoleamine 2,3-Dioxygenase and tolerance: Where are we now?","volume":"8","author":"Mellor","year":"2017","journal-title":"Front Immunol"},{"key":"key20210811132356_b46-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.4049\/jimmunol.0900986","article-title":"IDO activates regulatory T cells and blocks their conversion into Th17-Like T cells","volume":"183","author":"Baban","year":"2009","journal-title":"J Immuno"},{"key":"key20210811132356_b47-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"5542","DOI":"10.7150\/thno.35343","article-title":"Enhanced cancer therapy through synergetic photodynamic\/immune checkpoint blockade mediated by a liposomal conjugate comprised of porphyrin and IDO inhibitor","volume":"9","author":"Huang","year":"2019","journal-title":"Theranostics"},{"key":"key20210811132356_b48-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3389\/fimmu.2019.00949","article-title":"Myeloid-derived suppressor cells: Ductile targets in disease","volume":"10","author":"Consonni","year":"2019","journal-title":"Front Immunol"},{"key":"key20210811132356_b49-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3389\/fimmu.2019.01099","article-title":"Myeloid-derived suppressor cells: Not only in tumor immunity","volume":"10","author":"Pawelec","year":"2019","journal-title":"Front Immunol"},{"key":"key20210811132356_b50-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"55723","DOI":"10.1021\/acsami.0c18180","article-title":"Circumventing myeloid-derived suppressor cell-mediated immunosuppression using an oxygen-generated and -economized nanoplatform","volume":"12","author":"Zuo","year":"2020","journal-title":"ACS ACS Appl Mater Interfaces"},{"key":"key20210811132356_b51-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br J Cancer"},{"key":"key20210811132356_b52-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.semcancer.2012.01.011","article-title":"Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression","volume":"22","author":"Ostrand-Rosenberg","year":"2012","journal-title":"Semin Cancer Biol"},{"key":"key20210811132356_b53-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3389\/fimmu.2019.00771","article-title":"Myeloid derived suppressor cells interactions with natural killer cells and pro-angiogenic activities: Roles in tumor progression","volume":"10","author":"Bruno","year":"2019","journal-title":"Fronti Immunol"},{"key":"key20210811132356_b54-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s00262-013-1396-8","article-title":"Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer","volume":"62","author":"Iclozan","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"key20210811132356_b55-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/ph12040163","article-title":"Fighting hypoxia to improve PDT","volume":"12","author":"Larue","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"key20210811132356_b56-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"119699","DOI":"10.1016\/j.biomaterials.2019.119699","article-title":"Integration of immunogenic activation and immunosuppressive reversion using mitochondrial-respiration-inhibited platelet-mimicking nanoparticles","volume":"232","author":"Mai","year":"2020","journal-title":"Biomaterials"},{"key":"key20210811132356_b57-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.7150\/thno.27598","article-title":"Two-stage oxygen delivery for enhanced radiotherapy by perfluorocarbon nanoparticles","volume":"8","author":"Zhou","year":"2018","journal-title":"Theranostics"},{"key":"key20210811132356_b58-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/jbm.b.34071","article-title":"Self-production of oxygen system CaO2\/MnO2 @PDA-MB for the photodynamic therapy research and switch-control tumor cell imaging","volume":"106","author":"Ji","year":"2018","journal-title":"J Biomed Mater Res B Appl Biomater"},{"key":"key20210811132356_b59-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/labinvest.2010.205","article-title":"Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model","volume":"91","author":"Cao","year":"2011","journal-title":"Lab Invest"},{"key":"key20210811132356_b60-ol-0-0-12925","first-page":"3956","article-title":"Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response","volume":"62","author":"Ferrario","year":"2002","journal-title":"Cancer Res"},{"key":"key20210811132356_b61-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ebiom.2019.06.016","article-title":"Clearance of apoptotic cells by mesenchymal stem cells contributes to immunosuppression via PGE2","volume":"45","author":"Zhang","year":"2019","journal-title":"EBioMedicine"},{"key":"key20210811132356_b62-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1158\/1078-0432.CCR-18-1163","article-title":"The COX2 effector microsomal PGE2 synthase 1 is a regulator of immunosuppression in cutaneous melanoma","volume":"25","author":"Kim","year":"2019","journal-title":"Clin Cancer Res"},{"key":"key20210811132356_b63-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/978-1-60761-697-9_9","article-title":"Targeting the tumor microenvironment using photodynamic therapy combined with inhibitors of cyclooxygenase-2 or vascular endothelial growth factor","volume":"635","author":"Ferrario","year":"2010","journal-title":"Methods Mol Biol"},{"key":"key20210811132356_b64-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/09546630902882048","article-title":"Treatment of actinic keratoses on the dorsum of the hands: ALA-PDT versus diclofenac 3% gel followed by ALA-PDT. A placebo-controlled, double-blind, pilot study","volume":"20","author":"Van der Geer","year":"2009","journal-title":"J Dermatolog Treat"},{"key":"key20210811132356_b65-ol-0-0-12925","first-page":"93080Q","article-title":"Topical calcitriol prior to photodynamic therapy enhances treatment efficacy in non-melanoma skin cancer mouse models","volume":"9308","author":"Rollakanti","year":"2015","journal-title":"Proc SPIE Int Soc Opt Eng"},{"key":"key20210811132356_b66-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"748","DOI":"10.21037\/atm.2019.11.102","article-title":"Vitamin D alleviates acute graft-versus-host disease through promoting the generation of Foxp3+ T cells","volume":"7","author":"Ni","year":"2019","journal-title":"Ann Transl Med"},{"key":"key20210811132356_b67-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.jaci.2011.01.068","article-title":"Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells","volume":"127","author":"van der Aar","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"key20210811132356_b68-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"e125476","DOI":"10.1172\/jci.insight.125476","article-title":"Skin cancer precursor immunotherapy for squamous cell carcinoma prevention","volume":"4","author":"Rosenberg","year":"2019","journal-title":"JCI Insight"},{"key":"key20210811132356_b69-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/j.1751-1097.2010.00746.x","article-title":"Nicotinamide prevents ultraviolet radiation-induced cellular energy loss","volume":"86","author":"Park","year":"2010","journal-title":"Photochem Photobiol"},{"key":"key20210811132356_b70-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/01635589709514618","article-title":"Prevention of photoimmunosuppression and photocarcinogenesis by topical nicotinamide","volume":"29","author":"Gensler","year":"1997","journal-title":"Nutr Cancer"},{"key":"key20210811132356_b71-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1207\/S15327914NC340105","article-title":"Oral niacin prevents photocarcinogenesis and photoimmunosuppression in mice","volume":"34","author":"Gensler","year":"1999","journal-title":"Nutr Cancer"},{"key":"key20210811132356_b72-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1365-2133.2012.11109.x","article-title":"Nicotinamide reduces photodynamic therapy-induced immunosuppression in humans","volume":"167","author":"Thanos","year":"2012","journal-title":"Br J Dermatol"},{"key":"key20210811132356_b73-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/jid.2011.459","article-title":"Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials","volume":"132","author":"Surjana","year":"2012","journal-title":"J Invest Dermatol"},{"key":"key20210811132356_b74-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s001250051536","article-title":"Safety of high-dose nicotinamide: A review","volume":"43","author":"Knip","year":"2000","journal-title":"Diabetologia"},{"key":"key20210811132356_b75-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"296","DOI":"10.2307\/3577919","article-title":"Oxygen consumption and diffusion effects in photodynamic therapy","volume":"126","author":"Foster","year":"1991","journal-title":"Radiat Res"},{"key":"key20210811132356_b76-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/jid.2010.429","article-title":"Photodynamic therapy-induced immunosuppression in humans is prevented by reducing the rate of light delivery","volume":"131","author":"Frost","year":"2011","journal-title":"J Invest Dermatol"},{"key":"key20210811132356_b77-ol-0-0-12925","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1111\/j.1365-2133.2004.06211.x","article-title":"Photodynamic therapy of actinic keratosis at varying fluence rates: Assessment of photobleaching, pain and primary clinical outcome","volume":"151","author":"Ericson","year":"2004","journal-title":"Br J Dermatol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T10:24:16Z","timestamp":1628677456000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2021.12925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":77,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,7,14]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2021.12925","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,14]]},"article-number":"664"}}